# Mangalam Drugs And Organics (NSE: MANGALAM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MANGALAM · Pivot · prices to 22 Oct 2026

Mangalam Drugs And Organics (NSE: MANGALAM) closed at ₹29.66 on 22 Oct 2026, down 3.07% on the day. With a market capitalisation of ₹47 Cr, it ranks 3106th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −43.1% in FY26. Over the past year the share price has fallen 58.5%. Its 52-week range is ₹22.80 (29 Dec 2025) to ₹71.99 (23 Oct 2025); the last close is 58.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹67 Cr (−7.5% year on year) and net profit −₹13 Cr (−22,466.7%), on a consolidated basis. Promoters held 35.65% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹29.66 |
| Market cap | ₹47 Cr |
| ROE | −43.1% (FY26) |
| ROCE | −27.3% (FY26) |
| Debt to equity | 1.02 |
| 52-week high | ₹71.99 (23 Oct 2025) |
| 52-week low | ₹22.80 (29 Dec 2025) |
| 1-year return | −58.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹67 Cr | −7.5% | −₹13 Cr | −22,466.7% | −₹8.48 |
| Q3 FY26 | ₹58 Cr | −34.1% | −₹10 Cr | −862.8% | −₹6.21 |
| Q2 FY26 | ₹49 Cr | −38.4% | −₹7 Cr | −373.2% | −₹4.64 |
| Q1 FY26 | ₹57 Cr | −25.2% | −₹14 Cr | −614.9% | −₹8.72 |
| Q4 FY25 | ₹73 Cr | −28.6% | ₹0 Cr | −98.3% | ₹0.04 |
| Q3 FY25 | ₹89 Cr | −9.0% | ₹1 Cr | +158.0% | ₹0.81 |
| Q2 FY25 | ₹80 Cr | — | ₹3 Cr | — | ₹1.70 |
| Q1 FY25 | ₹76 Cr | — | ₹3 Cr | — | ₹1.70 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹318 Cr | ₹7 Cr |
| FY24 | ₹369 Cr | −₹9 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 35.65%
- Foreign institutions: 0.11%
- Domestic institutions: 0.00%
- Non-institutions: 64.24%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Shree Pacetroni](https://app.pivotnow.in/stock/SHREEPAC) | — | ₹50 Cr | — | — |
| [Biofil Chemicals & Pharmaceuticals](https://app.pivotnow.in/stock/BIOFILCHEM) | ₹30.00 | ₹49 Cr | 17.5 | — |
| [Shanmuga Hospit](https://app.pivotnow.in/stock/SHANMUGA) | — | ₹48 Cr | — | — |
| [Amkay Products](https://app.pivotnow.in/stock/AMKAY) | — | ₹46 Cr | — | — |
| [Shelter Pharma](https://app.pivotnow.in/stock/SHELTER) | — | ₹46 Cr | — | — |
| [Vista Pharma](https://app.pivotnow.in/stock/VISTAPH) | — | ₹45 Cr | — | — |

## Questions and answers

### What is the share price of Mangalam Drugs And Organics today?

Mangalam Drugs And Organics (NSE: MANGALAM) last closed at ₹29.66 on 22 Oct 2026. Its 52-week high is ₹71.99 and its 52-week low is ₹22.80.

### What is the market cap of Mangalam Drugs And Organics?

Mangalam Drugs And Organics' market capitalisation is ₹47 Cr (₹47 Cr) at the 22 Oct 2026 close, ranking 3106th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Mangalam Drugs And Organics?

Return on equity was −43.1% in FY26 and return on capital employed was −27.3% in FY26 (consolidated figures).

### Is Mangalam Drugs And Organics a debt-free company?

No. Mangalam Drugs And Organics' debt-to-equity ratio was 1.02 in FY26, with total debt of ₹9 Cr.

### What were Mangalam Drugs And Organics' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Mangalam Drugs And Organics reported revenue of ₹67 Cr, −7.5% year on year, and net profit of −₹13 Cr, −22,466.7% year on year.

### How has Mangalam Drugs And Organics stock performed over the last year?

Mangalam Drugs And Organics' share price has fallen 58.5% over the past year, +8.8% over three months and −9.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Mangalam Drugs And Organics?

As of 30 Jun 2026: promoters 35.65%, foreign institutions 0.11%, domestic institutions 0.00%, non-institutions 64.24%.

### Who are Mangalam Drugs And Organics' competitors?

The listed Pharma & Healthcare companies closest to Mangalam Drugs And Organics by market cap are Shree Pacetroni, Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit, Amkay Products, Shelter Pharma and Vista Pharma.

### Is Mangalam Drugs And Organics a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Mangalam Drugs And Organics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MANGALAM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.